Article Details

Zolgensma flatlines, but Spinraza isn't the beneficiary

Retrieved on: 2021-04-27 15:00:00

Tags for this article:

Click the tags to see associated articles and topics

Zolgensma flatlines, but Spinraza isn't the beneficiary. View article details on hiswai:

Excerpt

Roche's Evrysdi, an oral drug licensed from PTC Therapeutics, posted first-quarter US sales of CHF79m ($86m), a 72% quarter-on-quarter increase in ...

Article found on: www.evaluate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up